Skip to main content
OpenTrials
Completed

NCT Number: NCT00863265

Phytosterols, Ezetimibe, and Cholesterol Metabolism

Phytosterols and ezetimibe each reduce intestinal cholesterol absorption by 30-55% but appear to have different mechanisms of action. The investigators' hypothesis is that phytosterols and ezetimibe given together will block cholesterol absorption in an additive fashion. In a randomized, placebo-controlled crossover trial the effects of placebo, ezetimibe treatment and ezetimibe plus phytosterol treatment will be measured.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Center for Advance Nutrition at Utah State University

Logan, Utah, 84322-4715, United States

About this study

The investigators will perform a randomized, placebo-controlled crossover feeding study in 25 subjects with greater than ideal levels of LDL cholesterol who do not require anti-cholesterol drug treatment. Subjects will consume a baseline diet provided by a feeding center that is deficient in phytosterols for three periods of 21 days separated by 7-day washout periods. Treatments will be given in random order During period B placebo phytosterols and placebo ezetimibe will be given; during period C placebo phytosterols and active ezetimibe will be given; during period A active phytosterols and active ezetimibe will be given. Study endpoints are fecal cholesterol excretion and percent cholesterol absorption determined by gas chromatography/mass spectrometry and circulating LDL cholesterol.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female of any race or ethnicity between 18 to 80 years of age;
  • Body mass index between 20 - 35 kg/m2;
  • LDL-cholesterol between 130 - 189 mg/dL based on the average of duplicate screening measures. If the two LDL-C levels differ by more than 30 mg/dL, a third test will be scheduled with all three results averaged;
  • Free of chronic disease;
  • Willing to eat only the foods that are provided by the Center during the diet periods;
  • Willing to abstain from the consumption of alcohol for 48-hours prior to blood draw days;
  • Willing to drink no more than 5 cups of caffeine-containing beverages a day.

Exclusion criteria

  • Age < 18 or > 80 years;
  • Based on duplicate screening laboratory values: 1)LDL-C >=190 mg/dL; 2)TG >=250 mg/dL;3)blood pressure >= 160 mm Hg systolic or 95 mm Hg diastolic;
  • Documented presence of atherosclerotic disease;
  • Diabetes mellitus;
  • Renal, hepatic, endocrine, gastrointestinal, hematological or other systemic disease;
  • Body mass index > 35;
  • For women, pregnancy, breast feeding or postpartum < 6 months;
  • For women, peri-menopausal;
  • For women, sexually active but not practicing effective birth control methods;
  • History of drug or alcohol abuse;
  • History of depression or mental illness requiring treatment or medication within the last 6 months;
  • multiple food allergies or significant food preferences or restrictions that would interfere with diet adherence;
  • Chronic use of over-the-counter medication which would interfere with study endpoints including laxatives and antacids;
  • Lifestyle or schedule incompatible with the study protocol;
  • Planned continued use of dietary supplements through the study trial;
  • Taking any lipid-lowering, or other medications known to affect blood cholesterol.

Treatment and study plan

ezetimibe

Drug

Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.

Other names: C

Phytosterols + ezetimibe

Other

Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.

Other names: A

Placebo

Other

Other names: B

Primary outcomes

  1. Cholesterol Excretion

    Time frame: At the end of week 3 on each diet

    Milligrams of fecal cholesterol and cholesterol metabolites excreted per day

  2. Percent Cholesterol Absorption

    Time frame: Determined on the final 5 days of each dietary period

    Percent of intestinal cholesterol absorbed. Intestinal cholesterol is comprised of dietary cholesterol intake and endogenous cholesterol secreted into the intestinal lumen. Cholesterol absorption is the percent of intestinal cholesterol that is taken back up into the body and excluded from fecal excretion. It is also referred to as the efficiency of intestinal cholesterol absorption.

  3. LDL Cholesterol

    Time frame: At the end of week 3 on each diet

Sponsors and collaborators

Lead sponsor

Washington University School of Medicine

Other

Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)
  • Utah State University

Registry information

Official study title

Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3)

Acronym: Phyteaux-III

Important dates

Study start
2009
Primary completion
2009
Study completion
2010
First posted
Mar 17, 2009
Registry last updated
Jun 1, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.